These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 3815728)

  • 1. Abrogation of the prognostic significance of low leukemic cell retention of cytosine arabinoside triphosphate by intensification of therapy and by alteration in the dose and schedule of administration of cytosine arabinoside.
    Preisler HD; Rustum YM; Azarnia N; Priore R
    Cancer Chemother Pharmacol; 1987; 19(1):69-74. PubMed ID: 3815728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between leukemic cell retention of cytosine arabinoside triphosphate and the duration of remission in patients with acute non-lymphocytic leukemia.
    Preisler HD; Rustum Y; Priore RL
    Eur J Cancer Clin Oncol; 1985 Jan; 21(1):23-30. PubMed ID: 4038655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in the intracellular pharmacokinetics of cytosine arabinoside (AraC) between circulating leukemic blasts and normal mononuclear blood cells.
    Hiddemann W; Schleyer E; Unterhalt M; Zühlsdorf M; Rolf C; Reuter C; Kewer U; Uhrmeister C; Wörmann B; Büchner T
    Leukemia; 1992 Dec; 6(12):1273-80. PubMed ID: 1453772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing therapy for acute myeloid leukemia based on differences in intracellular metabolism of cytosine arabinoside between leukemic blasts and normal mononuclear blood cells.
    Hiddemann W; Schleyer E; Unterhalt M; Kern W; Büchner T
    Ther Drug Monit; 1996 Aug; 18(4):341-9. PubMed ID: 8857548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytosine arabinoside transport and metabolism in acute leukemias and T cell lymphoblastic lymphoma.
    Wiley JS; Taupin J; Jamieson GP; Snook M; Sawyer WH; Finch LR
    J Clin Invest; 1985 Feb; 75(2):632-42. PubMed ID: 3871794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Saturation of intracellular cytosine arabinoside triphosphate accumulation in human leukemic blast cells.
    Jamieson GP; Snook MB; Wiley JS
    Leuk Res; 1990; 14(5):475-9. PubMed ID: 2345470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytosine arabinoside in the treatment of T-cell acute lymphoblastic leukemia.
    Wiley JS; Woodruff RK; Jamieson GP; Firkin FC; Sawyer WH
    Aust N Z J Med; 1987 Aug; 17(4):379-86. PubMed ID: 3501710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of timing of high-dose cytosine arabinoside intensification and of maintenance therapy in the treatment of children with acute nonlymphocytic leukemia.
    Woods WG; Ruymann FB; Lampkin BC; Buckley JD; Bernstein ID; Srivastava AK; Smithson WA; Benjamin DR; Feig SA; Kim TH
    Cancer; 1990 Sep; 66(6):1106-13. PubMed ID: 2205352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia.
    Herzig RH; Lazarus HM; Wolff SN; Phillips GL; Herzig GP
    J Clin Oncol; 1985 Jul; 3(7):992-7. PubMed ID: 3894588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytosine arabinoside deamination in human leukaemic myeloblasts and resistance to cytosine arabinoside therapy.
    Harris AL; Grahame-Smith DG; Potter CG; Bunch C
    Clin Sci (Lond); 1981 Feb; 60(2):191-8. PubMed ID: 6940687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Intracellular retention of cytarabine-triphosphate (Ara-CTP) in blasts of children with acute lymphoblastic leukemia. Correlation with clinical course parameters].
    Schiller M; Hohenlöchter B; Schulze-Westhoff P; Zimmermann M; Ritter J; Jürgens H; Boos J
    Klin Padiatr; 1996; 208(4):151-9. PubMed ID: 8926681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful modulation of high-dose cytosine arabinoside metabolism in acute myeloid leukaemia by haematopoietic growth factors: no effect of ribonucleotide reductase inhibitors fludarabine and gemcitabine.
    Braess J; Wegendt C; Jahns-Streubel G; Kern W; Keye S; Unterhalt M; Schleyer E; Hiddemann W
    Br J Haematol; 2000 May; 109(2):388-95. PubMed ID: 10848830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose versus intermediate-dose cytosine arabinoside in combination with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia--preliminary clinical and pharmacological data of a randomized comparison.
    Hiddemann W; Schleyer E; Uhrmeister C; Aul CH; Maschmeyer G; Heinecke A; Büchner T
    Cancer Treat Rev; 1990 Sep; 17(2-3):279-85. PubMed ID: 2272043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytosine arabinoside in experimental combination therapy.
    Edelstein M; Valeriote F
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):75-83. PubMed ID: 3892705
    [No Abstract]   [Full Text] [Related]  

  • 15. Prediction of response of acute nonlymphocytic leukaemia to therapy with 'high dose' cytosine arabinoside.
    Preisler HD; Epstein J; Barcos M; Priore R; Raza A; Browman GP; Vogler R; Winton E; Grunwald H; Rai K
    Br J Haematol; 1984 Sep; 58(1):19-32. PubMed ID: 6466567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two simple high-performance liquid chromatographic methods for simultaneous determination of 2'-deoxycytidine 5'-triphosphate and cytosine arabinoside 5'-triphosphate concentrations in biological samples.
    Danks MK
    J Chromatogr; 1982 Dec; 233():141-8. PubMed ID: 7161328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Induction of remission by sequential treatment with cytosine arabinoside (araC/high dose) and L-asparaginase].
    Martín-Aragonés G; Sanz MA; Martínez JA; Rafecas FJ; Gomis F; Lorenzo I; Sanz G; Marty ML
    Sangre (Barc); 1985; 30(1):15-21. PubMed ID: 3859023
    [No Abstract]   [Full Text] [Related]  

  • 18. High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: an update.
    Wolff SN; Herzig RH; Phillips GL; Lazarus HM; Greer JP; Stein RS; Ray WA; Herzig GP
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):12-7. PubMed ID: 3589687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of childhood acute lymphoblastic leukemia with intermediate-dose cytosine arabinoside and adriamycin.
    Ishii E; Hara T; Ohkubo K; Matsuzaki A; Takeuchi T; Ueda K
    Med Pediatr Oncol; 1986; 14(2):73-7. PubMed ID: 3458999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapeutic results of DCMP therapy (2M-80) in acute non-lymphocytic leukemia--the relationship between the residual leukemic cells and duration of remission].
    Moriyama Y; Urushiyama M; Ohnishi M; Koyama S; Hirosawa H; Hanano M; Fuse I; Takai K; Nagayama R; Fujiwara M; Kishi K; Takahashi M; Koike T; Sakai C; Kashimura M; Miura R; Aoyagi A; Sanada M; Hattori A; Shibata A; Shinada S
    Gan To Kagaku Ryoho; 1982 Sep; 9(9):1549-54. PubMed ID: 6892201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.